The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
111343892 11134389 2 F 20150430 20160823 20150525 20160905 EXP US-ROCHE-1581082 ROCHE 40.00 YR M Y 131.00000 KG 20160905 MD US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
111343892 11134389 1 PS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 1. U 125085 2040 MG INFUSION
111343892 11134389 2 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 5 U 125085 1929 MG INFUSION
111343892 11134389 3 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 6 U 125085 1950 MG INFUSION
111343892 11134389 4 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 7 U 125085 1958 MG INFUSION
111343892 11134389 5 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 4 U 125085 1860 MG INFUSION
111343892 11134389 6 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 14 U 125085 2025 MG INFUSION
111343892 11134389 7 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 15 U 125085 2040 MG INFUSION
111343892 11134389 8 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 16 U 125085 2025 MG INFUSION
111343892 11134389 9 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 17 U 125085 1995 MG INFUSION
111343892 11134389 10 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 18 U 125085 2025 MG INFUSION
111343892 11134389 11 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 19 U 125085 2025 MG INFUSION
111343892 11134389 12 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 20 U 125085 2010 MG INFUSION
111343892 11134389 13 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 12 U 125085 2025 MG INFUSION
111343892 11134389 14 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 13 U 125085 2025 MG INFUSION
111343892 11134389 15 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 8 U 125085 1977 MG INFUSION
111343892 11134389 16 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 9 U 125085 1950 MG INFUSION
111343892 11134389 17 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 10 U 125085 1965 MG INFUSION
111343892 11134389 18 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 11 U 125085 2025 MG INFUSION
111343892 11134389 19 SS Bevacizumab BEVACIZUMAB 1 Intravenous (not otherwise specified) COURSE 02 U 125085 2040 MG INFUSION
111343892 11134389 20 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 1. Y 0 408 MG
111343892 11134389 21 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 4. Y 0 372 MG
111343892 11134389 22 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 16. Y 0 405 MG
111343892 11134389 23 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 20. Y 0 402 MG
111343892 11134389 24 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 3. Y 0 393 MG
111343892 11134389 25 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 12. Y 0 405 MG
111343892 11134389 26 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 2. Y 0 408 MG
111343892 11134389 27 SS IPILIMUMAB IPILIMUMAB 1 Intravenous (not otherwise specified) COURSE 8. Y 0 395 MG
111343892 11134389 28 C HCTZ HYDROCHLOROTHIAZIDE 1 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
111343892 11134389 1 Malignant melanoma
111343892 11134389 20 Malignant melanoma

Outcome of event

Event ID CASEID OUTC COD
111343892 11134389 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
111343892 11134389 Hypertension
111343892 11134389 Hyperuricaemia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
111343892 11134389 1 20150319 0
111343892 11134389 2 20150611 0
111343892 11134389 3 20150702 0
111343892 11134389 4 20150727 0
111343892 11134389 5 20150521 0
111343892 11134389 6 20151217 0
111343892 11134389 7 20160114 0
111343892 11134389 8 20160201 0
111343892 11134389 9 20160303 0
111343892 11134389 10 20160323 0
111343892 11134389 11 20160413 0
111343892 11134389 12 20160505 0
111343892 11134389 13 20151104 0
111343892 11134389 14 20151125 0
111343892 11134389 15 20150814 0
111343892 11134389 16 20150903 0
111343892 11134389 17 20150924 0
111343892 11134389 18 20151014 0
111343892 11134389 19 20150409 0
111343892 11134389 20 20150319 0
111343892 11134389 21 20150521 0
111343892 11134389 22 20160201 0
111343892 11134389 23 20160505 0
111343892 11134389 24 20150430 0
111343892 11134389 25 20151104 0
111343892 11134389 26 20150409 0
111343892 11134389 27 20150814 0

Execution Time: 0.0070481300354004 seconds (ucode:5106610). Developed by: James D. Barger

 


another James Barger innovation
All original content on this site is © 2013-2024 James D. Barger and SafetyRates.com.